|
1
|
Carvalho C, Santos RX, Cardoso S, Correia
S, Oliveira PJ, Santos MS and Moreira PI: Doxorubicin: The good,
the bad and the ugly effect. Curr Med Chem. 16:3267–3285. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singal PK and Iliskovic N:
Doxorubicin-induced cardiomyopathy. N Engl J Med. 339:900–905.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Y, Zheng D, Wei M, Ma J, Yu Y, Chen
R, Lacefield JC, Xu H and Peng T: Over-expression of calpastatin
aggravates cardiotoxicity induced by doxorubicin. Cardiovasc Res.
98:381–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ohtake S, Miyawaki S, Fujita H, Kiyoi H,
Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y,
et al: Randomized study of induction therapy comparing
standard-dose idarubicin with high-dose daunorubicin in adult
patients with previously untreated acute myeloid leukemia: The
JALSG AML201 study. Blood. 117:2358–2365. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goh BC, Lee SC, Wang LZ, Fan L, Guo JY,
Lamba J, Schuetz E, Lim R, Lim HL, Ong AB and Lee HS: Explaining
interindividual variability of docetaxel pharmacokinetics and
pharmacodynamics in Asians through phenotyping and genotyping
strategies. J Clin Oncol. 20:3683–3690. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ro H, Min SI, Yang J, Moon KC, Kim YS, Kim
SJ, Ahn C and Ha J: Impact of tacrolimus intraindividual
variability and CYP3A5 genetic polymorphism on acute rejection in
kidney transplantation. Ther Drug Monit. 34:680–685. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH,
Lee JS and Ahn SH: Prospective evaluation of the drug-metabolizing
enzyme polymorphisms and toxicity profile of docetaxel in Korean
patients with operable lymph node-positive breast cancer receiving
adjuvant chemotherapy. Cancer Chemother Pharmacol. 69:1221–1227.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Afsar NA, Ufer M, Haenisch S, Remmler C,
Mateen A, Usman A, Ahmed KZ, Ahmad HR and Cascorbi I: Relationship
of drug metabolizing enzyme genotype to plasma levels as well as
myelotoxicity of cyclophosphamide in breast cancer patients. Eur J
Clin Pharmacol. 68:389–395. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lopes BA, Emerenciano M, Gonçalves BA,
Vieira TM, Rossini A and Pombo-de-Oliveira MS: Polymorphisms in
CYP1B1, CYP3A5, GSTT1, and SULT1A1 are associated with early age
acute leukemia. PLoS One. 10:e01273082015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma LM, Liu HC, Ruan LH and Feng YM:
CYP3A5*3 genetic polymorphism is associated with childhood acute
lymphoblastic leukemia risk: A meta-analysis. Biomed J. 38:428–432.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Zou Y, Wang H, Chen X, Ruan M, Chen
Y, Yang W, Guo Y, Liu T, Zhang L, et al: Treatment outcome of
childhood standard-risk and median-risk acute lymphoblastic
leukemia with CCLG-2008 protocol. Zhonghua Er Ke Za Zhi.
52:449–454. 2014.(In Chinese). PubMed/NCBI
|
|
12
|
Florescu M, Cinteza M and Vinereanu D:
Chemotherapy-induced cardiotoxicity. Maedica (Buchar). 8:59–67.
2013.PubMed/NCBI
|
|
13
|
Stankov K, Sabo A and Mikov M:
Pharmacogenetic biomarkers as tools for pharmacoepidemiology of
severe adverse drug reactions. Drug Dev Res. 74:1–14. 2013.
View Article : Google Scholar
|
|
14
|
Francis J, Dubashi B, Sundaram R, Pradhan
SC and Chandrasekaran A: A study to explore the correlation of
ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level
concentration with imatinib mesylate-induced thrombocytopenia in
chronic myeloid leukemia patients. Cancer Chemother Pharmacol.
76:1185–1189. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hareedy MS, El Desoky ES, Woillard JB,
Thabet RH, Ali AM, Marquet P and Picard N: Genetic variants in
6-mercaptopurine pathway as potential factors of hematological
toxicity in acute lymphoblastic leukemia patients.
Pharmacogenomics. 16:1119–1134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fetterly GJ, Aras U, Lal D, Murphy M,
Meholick PD and Wang ES: Development of a preclinical PK-PD model
to assess antitumor response of a sequential aflibercept and
doxorubicin-dosing strategy in acute myeloid leukemia. AAPS J.
15:662–673. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M,
Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al:
Sequence diversity in CYP3A promoters and characterization of the
genetic basis of polymorphic CYP3A5 expression. Nat Genet.
27:383–391. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seng KY, Hee KH, Soon GH, Sapari NS, Soong
R, Goh BC and Lee LS: CYP3A5*3 and bilirubin predict midazolam
population pharmacokinetics in Asian cancer patients. J Clin
Pharmacol. 54:215–224. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kokenberg E, Sonneveld P, Delwel R, Sizoo
W, Hagenbeek A and Löwenberg B: In vivo uptake of daunorubicin by
acute myeloid leukemia (AML) cells measured by flow cytometry.
Leukemia. 2:511–517. 1988.PubMed/NCBI
|
|
20
|
Bogason A, Quartino AL, Lafolie P,
Masquelier M, Karlsson MO, Paul C, Gruber A and Vitols S: Inverse
relationship between leukaemic cell burden and plasma
concentrations of daunorubicin in patients with acute myeloid
leukaemia. Br J Clin Pharmacol. 71:514–521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chien JY and Ho RJ: Drug delivery trends
in clinical trials and translational medicine: Evaluation of
pharmacokinetic properties in special populations. J Pharm Sci.
100:53–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
